Asano et al. reported that positive AR expression had a worse prognosis for both overall survival (p = 0.002) and disease-free survival (p = 0.006) in triple-negative breast cancer patients who received neoadjuvant chemotherapy, but had no association in non-triple-negative breast cancers [12]. The gene discussed is AR; the disease is triple-negative breast carcinoma.